Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02136134
Title Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ESP | DEU | AUS

Facility Status City State Zip Country Details
Birmingham Alabama United States Details
Los Angeles California United States Details
Stamford Connecticut United States Details
Jacksonville Florida United States Details
Atlanta Georgia United States Details
Niles Illinois United States Details
Topeka Kansas United States Details
Westwood Kansas United States Details
Marrero Louisiana United States Details
Boston Massachusetts United States Details
Lansing Michigan United States Details
New York New York United States Details
Chapel Hill North Carolina United States Details
Portland Oregon United States Details
Philadelphia Pennsylvania United States Details
Providence Rhode Island United States Details
Seattle Washington United States Details
Adelaide Australia Details
Concord Australia Details
Fitzroy Australia Details
Hobart Australia Details
Melbourne Australia Details
Nedlands Australia Details
Woodville South Australia Details
Barretos Brazil Details
Porto Alegre Brazil Details
Salvador Brazil Details
Sao Paulo Brazil Details
São Paulo Brazil Details
Brno Czechia Details
Hradec Kralove Czechia Details
Ostrava-Poruba Czechia Details
Praha 10 Czechia Details
Praha 2 Czechia Details
Bamberg Germany Details
Berlin Germany Details
Duesseldorf Germany Details
Freiburg Germany Details
Göttingen Germany Details
Hamburg Germany Details
Mainz Germany Details
München Germany Details
Stuttgart Germany Details
Tübingen Germany Details
Ulm Germany Details
Würzburg Germany Details
Budapest Hungary Details
Debrecen Hungary Details
Győr Hungary Details
Pecs Hungary Details
Veszprém Hungary Details
Busan Korea, Republic of Details
Hwasun Korea, Republic of Details
Seoul Korea, Republic of Details
Suwon Korea, Republic of Details
Ulsan Korea, Republic of Details
Huixquilucan Mexico Details
Monterrey Mexico Details
Alkmaar Netherlands Details
Amersfoort Netherlands Details
Den Haag Netherlands Details
Dordrecht Netherlands Details
Groningen Netherlands Details
Leiden Netherlands Details
Maastricht Netherlands Details
Nijmegen Netherlands Details
Chorzów Poland Details
Katowice Poland Details
Krakow Poland Details
Poznan Poland Details
Warszawa Poland Details
Krasnodar Russian Federation Details
Moscow Russian Federation Details
Nizhny Novgorod Russian Federation Details
Penza Russian Federation Details
Pyatigorsk Russian Federation Details
Ryazan Russian Federation Details
Samara Russian Federation Details
Sochi Russian Federation Details
Syktyvkar Russian Federation Details
Madrid Spain Details
Salamanca Spain Details
San Sebastian de los Reyes Spain Details
Toledo Spain Details
Valencia Spain Details
Linkoping Sweden Details
Lulea Sweden Details
Lund Sweden Details
Orebro Sweden Details
Sundsvall Sweden Details
Umea Sweden Details
Uppsala Sweden Details
Västerås Sweden Details
Ankara Turkey Details
Istanbul Turkey Details
Izmir Turkey Details
Kayseri Turkey Details
Kocaeli Turkey Details
Malatya Turkey Details
Cherkasy Ukraine Details
Dnepropetrovsk Ukraine Details
Ivano-Frankivsk Ukraine Details
Kiev Ukraine Details
Lviv Ukraine Details
Poltava Ukraine Details
Vinnitsa Ukraine Details
Zaporizhzhya Ukraine Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field